246 related articles for article (PubMed ID: 23627816)
1. Validation of self-reported cannabis dose and potency: an ecological study.
van der Pol P; Liebregts N; de Graaf R; Korf DJ; van den Brink W; van Laar M
Addiction; 2013 Oct; 108(10):1801-8. PubMed ID: 23627816
[TBL] [Abstract][Full Text] [Related]
2. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study.
van der Pol P; Liebregts N; Brunt T; van Amsterdam J; de Graaf R; Korf DJ; van den Brink W; van Laar M
Addiction; 2014 Jul; 109(7):1101-9. PubMed ID: 24628797
[TBL] [Abstract][Full Text] [Related]
3. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops.
Pijlman FT; Rigter SM; Hoek J; Goldschmidt HM; Niesink RJ
Addict Biol; 2005 Jun; 10(2):171-80. PubMed ID: 16191670
[TBL] [Abstract][Full Text] [Related]
4. Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?
Freeman TP; Morgan CJ; Hindocha C; Schafer G; Das RK; Curran HV
Addiction; 2014 Oct; 109(10):1686-94. PubMed ID: 24894801
[TBL] [Abstract][Full Text] [Related]
5. Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial.
Hjorthøj CR; Fohlmann A; Larsen AM; Arendt M; Nordentoft M
Addiction; 2012 Jun; 107(6):1123-31. PubMed ID: 22151583
[TBL] [Abstract][Full Text] [Related]
6. Increasing potency and price of cannabis in Europe, 2006-16.
Freeman TP; Groshkova T; Cunningham A; Sedefov R; Griffiths P; Lynskey MT
Addiction; 2019 Jun; 114(6):1015-1023. PubMed ID: 30597667
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cannabis timeline followback (EC-TLFB): Comprehensive assessment of cannabis use including standard THC units and validation through biological measures.
Petrilli K; Lawn W; Lees R; Mokrysz C; Borissova A; Ofori S; Trinci K; Dos Santos R; Leitch H; Soni S; Hines LA; Lorenzetti V; Curran HV; Freeman TP
Addiction; 2024 Apr; 119(4):772-783. PubMed ID: 38105033
[TBL] [Abstract][Full Text] [Related]
8. High potency cannabis use, mental health symptoms and cannabis dependence: Triangulating the evidence.
Petrilli K; Hines L; Adams S; Morgan CJ; Curran HV; Freeman TP
Addict Behav; 2023 Sep; 144():107740. PubMed ID: 37121087
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.
Schoedel KA; Chen N; Hilliard A; White L; Stott C; Russo E; Wright S; Guy G; Romach MK; Sellers EM
Hum Psychopharmacol; 2011 Apr; 26(3):224-36. PubMed ID: 21671456
[TBL] [Abstract][Full Text] [Related]
10. Estimating THC Consumption from Smoked and Vaped Cannabis Products in an Online Survey of Adults Who Use Cannabis.
Budney AJ; Borodovsky JT; Struble CA; Habib MI; Shmulewitz D; Livne O; Aharonovich E; Walsh C; Cuttler C; Hasin DS
Cannabis Cannabinoid Res; 2024 Apr; 9(2):688-698. PubMed ID: 36521175
[No Abstract] [Full Text] [Related]
11. Differential responses to cannabis potency: a typology of users based on self-reported consumption behaviour.
Korf DJ; Benschop A; Wouters M
Int J Drug Policy; 2007 May; 18(3):168-76. PubMed ID: 17689363
[TBL] [Abstract][Full Text] [Related]
12. Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis.
Cascini F; Aiello C; Di Tanna G
Curr Drug Abuse Rev; 2012 Mar; 5(1):32-40. PubMed ID: 22150622
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users.
Ramaekers JG; Kauert G; Theunissen EL; Toennes SW; Moeller MR
J Psychopharmacol; 2009 May; 23(3):266-77. PubMed ID: 18719045
[TBL] [Abstract][Full Text] [Related]
14. Cannabis with high cannabidiol content is associated with fewer psychotic experiences.
Schubart CD; Sommer IE; van Gastel WA; Goetgebuer RL; Kahn RS; Boks MP
Schizophr Res; 2011 Aug; 130(1-3):216-21. PubMed ID: 21592732
[TBL] [Abstract][Full Text] [Related]
15. Using ecological momentary assessment and a portable device to quantify standard tetrahydrocannabinol units for cannabis flower smoking.
Trull TJ; Freeman LK; Fleming MN; Vebares TJ; Wycoff AM
Addiction; 2022 Aug; 117(8):2351-2358. PubMed ID: 35293047
[TBL] [Abstract][Full Text] [Related]
16. Limitations to the Dutch cannabis toleration policy: Assumptions underlying the reclassification of cannabis above 15% THC.
Van Laar M; Van Der Pol P; Niesink R
Int J Drug Policy; 2016 Aug; 34():58-64. PubMed ID: 27471078
[TBL] [Abstract][Full Text] [Related]
17. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms.
Budney AJ; Vandrey RG; Hughes JR; Moore BA; Bahrenburg B
Drug Alcohol Depend; 2007 Jan; 86(1):22-9. PubMed ID: 16769180
[TBL] [Abstract][Full Text] [Related]
18. Cannabis smoke condensate I: the effect of different preparation methods on tetrahydrocannabinol levels.
Van der Kooy F; Pomahacova B; Verpoorte R
Inhal Toxicol; 2008 Jul; 20(9):801-4. PubMed ID: 18645719
[TBL] [Abstract][Full Text] [Related]
19. Higher average potency across the United States is associated with progression to first cannabis use disorder symptom.
Arterberry BJ; Treloar Padovano H; Foster KT; Zucker RA; Hicks BM
Drug Alcohol Depend; 2019 Feb; 195():186-192. PubMed ID: 30573162
[TBL] [Abstract][Full Text] [Related]
20. Medicinal Δ(9) -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests.
Bosker WM; Kuypers KP; Theunissen EL; Surinx A; Blankespoor RJ; Skopp G; Jeffery WK; Walls HC; van Leeuwen CJ; Ramaekers JG
Addiction; 2012 Oct; 107(10):1837-44. PubMed ID: 22553980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
